Image via Wikipedia
In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval.
GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]
Posted in Deals, News, Technology | Also tagged Amgen, Australia, Canada, denosumab, Dmab, GlaxoSmithKline, Market, Mexico, sales force, U.S. Food and Drug Administration, United States
PharmExec Blog
Follow Us
RSS
Bookstore
GSK Signs $120M Deal to Market DMab Overseas